150 related articles for article (PubMed ID: 34508266)
1. Secukinumab therapy in reactive arthritis: Report of two cases.
Padhan P; Maikap D
Mod Rheumatol Case Rep; 2022 Jan; 6(1):22-24. PubMed ID: 34508266
[TBL] [Abstract][Full Text] [Related]
2. Successful use of tofacitinib in reactive arthritis refractory to conventional therapies - a case series.
Maikap D; Padhan P
Mod Rheumatol Case Rep; 2022 Jun; 6(2):167-170. PubMed ID: 35024869
[TBL] [Abstract][Full Text] [Related]
3. Management of reactive arthritis.
Palazzi C; Olivieri I; D'Amico E; Pennese E; Petricca A
Expert Opin Pharmacother; 2004 Jan; 5(1):61-70. PubMed ID: 14680436
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and Safety of Tumor Necrosis Factor Inhibitors in Reactive Arthritis: A Nationwide Experience from Iceland.
Thorsteinsson B; Geirsson AJ; Krogh NS; Gudbjornsson B;
J Rheumatol; 2020 Oct; 47(10):1575-1581. PubMed ID: 32007931
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy.
Jensen AK; Chatzidionysiou K; Torp CK; Sørensen AS; Tenstad HB; Schäfer VS; Kostine M; Jacobsen S; Leipe J; Kragstrup TW
Biomed Pharmacother; 2022 Apr; 148():112687. PubMed ID: 35228067
[TBL] [Abstract][Full Text] [Related]
6. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
7. A retrospective case series of 12 patients with chronic reactive arthritis with emphasis on treatment outcome with biologics.
Gupta V; Mohta P; Sharma VK; Khanna N
Indian J Dermatol Venereol Leprol; 2021; 87(2):227-234. PubMed ID: 31293276
[TBL] [Abstract][Full Text] [Related]
8. Treatment of reactive arthritis with biological agents: a review.
Zeng H; Luo B; Zhang Y; Xie Z; Ye Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32039436
[TBL] [Abstract][Full Text] [Related]
9. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
12. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
14. Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature.
Bernini L; Manzini CU; Giuggioli D; Sebastiani M; Ferri C
Autoimmun Rev; 2013 Oct; 12(12):1150-9. PubMed ID: 23816569
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
Gandjour A; Ostwald DA
Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab: A Review in Psoriatic Arthritis.
Shirley M; Scott LJ
Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
[TBL] [Abstract][Full Text] [Related]
17. [Reactive arthritis - a disease almost forgotten?].
Märker-Hermann E
Dtsch Med Wochenschr; 2020 Dec; 145(24):1786-1790. PubMed ID: 33254255
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab: A Review in Psoriatic Arthritis.
Blair HA
Drugs; 2021 Mar; 81(4):483-494. PubMed ID: 33661486
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis.
Meyer A; Chatelus E; Wendling D; Berthelot JM; Dernis E; Houvenagel E; Morel J; Richer O; Schaeverbeke T; Gottenberg JE; Sibilia J;
Arthritis Rheum; 2011 May; 63(5):1274-80. PubMed ID: 21538314
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
